Endometrial cancer recurrent
Not recruitingStudy on the Safety and Effectiveness of Lurbinectedin and Dostarlimab for Patients with Advanced Endometrial Cancer After Platinum-based Chemotherapy
Study on the Safety and Effectiveness of Lurbinectedin and Dostarlimab for Patients with Advanced Endometrial Cancer After Platinum-based Chemotherapy
- Disease:Endometrial cancer recurrent
- Substances:DostarlimabLurbinectedin
Spain- Participants:18–64 years · 65+ years
- Substances:Dostarlimab
- Sponsor:Vall D Hebron Institute Of Oncology









